Annie Yoshiyama

CIK: 0001835208

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ALLO

Allogene Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

ALLO
Allogene Therapeutics, Inc.
Apr 21, 2026
Sale(S)
Direct
9.6K shares at avg. $2.31$22K
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
4.2K shares at avg. $1.72$7K
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to buy)
Direct
179.7K shares-
ALLO
Allogene Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Unit
Direct
50.8K shares-
ALLO
Allogene Therapeutics, Inc.
Apr 21, 2025
Sale(S)
Direct
9.6K shares at avg. $1.41$14K
ALLO
Allogene Therapeutics, Inc.
Jan 24, 2025
Award(A)
Direct
36.2K shares-

		Type	Shares	Price		Ownership
Apr 21, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	9,586	$2.31	$22,144	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Sale(S)	4,167	$1.72	$7,167	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Award(A) Stock Option (Right to buy)	179,691	-	-	Direct
Feb 2, 2026	ALLO Allogene Therapeutics, Inc.	Award(A) Restricted Stock Unit	50,827	-	-	Direct
Apr 21, 2025	ALLO Allogene Therapeutics, Inc.	Sale(S)	9,601	$1.41	$13,537	Direct
Jan 24, 2025	ALLO Allogene Therapeutics, Inc.	Award(A)	36,232	-	$0	Direct

1-6 of 6 transactions

About Yoshiyama Annie

Yoshiyama Annie (SEC CIK 0001835208) files insider reports with the SEC as SVP, Finance of Allogene Therapeutics, Inc. (ALLO).

Signal8 holds 4 ownership filings by Yoshiyama Annie, all Form 4s, filed between Jan 28, 2025 and Apr 23, 2026. Those filings report 6 transactions, from Jan 24, 2025 to Apr 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Yoshiyama Annie's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Yoshiyama Annie

Apr 21, 2026: Open-market sale of ALLO shares (Form 4, code S).
Feb 2, 2026: Open-market sale of ALLO shares (Form 4, code S).
Feb 2, 2026: Grants or awards of ALLO derivative securities (2 lines, Form 4, code A).
Apr 21, 2025: Open-market sale of ALLO shares (Form 4, code S).
Jan 24, 2025: Grant or award of ALLO shares (Form 4, code A).

Other insiders filing for Allogene Therapeutics, Inc. (ALLO)

Parker Geoffrey M., CHIEF FINANCIAL OFFICER
Douglas Earl Martin, SVP, General Counsel
Roberts Zachary, President and CEO
Kazam Joshua A, Director
MESSEMER DEBORAH M., Director
Mayo Stephen, Director

How to read Form 4 transaction codes